NCT00496756 - Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 1, 2007

Primary Completion Date

October 31, 2009

Study Completion Date

April 25, 2014

Conditions

Kidney Cancer

Interventions

DRUG

Sorafenib

initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg

Trial Locations (1)

68198

University of Nebraska Medical Center, Omaha